التفاصيل البيبلوغرافية
| العنوان: |
Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity. |
| المؤلفون: |
Dan, Aravot1,2 aravot_dan@clalit.org.il, Yaron, Barac D.1,2 yaronbar@icloud.com, Efrat, Krutzwald-Josefson1 Efratjo@clalit.org.il, Allen Aaron, M.3 allena@clalit.org.il, Dov, Flex3 dovf@clalit.org.il, Nir, Peled3 nirp@clalit.org.il, Kramer Mordechai, R.2,4 kramerm@clalit.org.il, Yuri, Peysakhovich1 yuripe1976@yahoo.com, Milton, Saute1,2 sautem@clalit.org.il, Aravot, Dan1,2 (AUTHOR), Barac, Yaron D1,2 (AUTHOR), Krutzwald-Josefson, Efrat1 (AUTHOR), Allen, Aaron M3 (AUTHOR), Flex, Dov3 (AUTHOR), Peled, Nir3 (AUTHOR), Kramer, Mordechai R2,4 (AUTHOR), Peysakhovich, Yuri1 (AUTHOR), Saute, Milton1,2 (AUTHOR) |
| المصدر: |
Journal of Cardiothoracic Surgery. 1/9/2019, Vol. 14 Issue 1, p1-7. 7p. |
| مصطلحات موضوعية: |
*NON-small-cell lung carcinoma, *PNEUMONECTOMY, *CHEMORADIOTHERAPY, *HOSPITAL care, *DISEASES |
| مستخلص: |
Introduction: Advanced non-small cell lung cancer (NSCLC) is still a therapeutic challenge as the 5-year survival is under 30%. The optimal treatment regimen is still under debate.Hypothesis: Neo adjuvant (NA) treatment given pre-pneumonectomy does not increase surgical complexity or peri-OP mortality while it has a potential to increase long term survival.Methods: We have conducted a retrospective study of 169 patients who underwent a pneumonectomy for NSCLC between January 2005 to December 2015 and focused on stage IIIa patients; a cohort of 51 patients, 30 which received neo adjuvant chemo-radiation (NA group) prior to pneumonectomy and 21 patients who had undergone pneumonectomy followed by adjuvant treatment (Adjuvant group). Surgical complexity and short- and long-term survival were evaluated. Surgical complexity was assessed by surrogates as surgery duration, hospitalization length and interdepartmental transfer.Results: While no statistically significant differences were found in surgery duration, hospitalization length, morbidity in the 1st year post-OP and the peri-OP mortality; The long term beneficiary effect among the neo adjuvant patients was clear; while 30% of the NA patients were alive 8 years post-OP, there were no survivors in the adjuvant group 5.5 years post-OP.Conclusion: We conclude that while NA treatment has no effect on operation complexity, peri-OP mortality or post-OP morbidity; its impact on long term survival is protuberant, therefore, we believe that NA treatment should be considered as the treatment of choice in advanced NSCLC in need for pneumonectomy. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder